Literature DB >> 20354347

Oral administration of acidic xylooligosaccharides prevents the development of atopic dermatitis-like skin lesions in NC/Nga mice.

Takayuki Ohbuchi1, Makoto Sakaino, Tetsunari Takahashi, Naoya Azumi, Kotaro Ishikawa, Sadahiro Kawazoe, Yukiko Kobayashi, Yasuhiro Kido.   

Abstract

We examined whether two types of xylooligosaccharides (neutral or acidic xylooligosaccharides) derived from hardwood kraft pulp ameliorate the development of atopic dermatitis (AD)-like skin lesions induced by repeated application of picryl chloride (PiCl) in NC/Nga mice. Oral administration of acidic xylooligosaccharides at a daily dose of 100 mg/kg significantly prevented the development of AD-like skin lesions. Serum histamine level was significantly suppressed, but serum total IgE level was not significantly suppressed. Moreover, the secretion of inflammatory cytokine IL-12 from splenic lymphocytes was significantly suppressed. On the other hand, neutral xylooligosaccharides showed no significant preventive effect on the development of AD-like symptoms. These results suggest that oral administration of acidic xylooligosaccharides may be effective in preventing the development of AD-like skin disease and one of the mechanisms is the suppressive effect on IL-12.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20354347     DOI: 10.3177/jnsv.56.54

Source DB:  PubMed          Journal:  J Nutr Sci Vitaminol (Tokyo)        ISSN: 0301-4800            Impact factor:   2.000


  2 in total

1.  GH30-7 Endoxylanase C from the Filamentous Fungus Talaromyces cellulolyticus.

Authors:  Yusuke Nakamichi; Tatsuya Fujii; Thierry Fouquet; Akinori Matsushika; Hiroyuki Inoue
Journal:  Appl Environ Microbiol       Date:  2019-10-30       Impact factor: 4.792

2.  Is pimecrolimus cream (1%) an appropriate therapeutic agent for the treatment of external ear atopic dermatitis?

Authors:  Güçlü Kaan Beriat; Sefik Halit Akmansu; Cem Doğan; Eren Taştan; Ferda Topal; Bizden Sabuncuoğlu
Journal:  Med Sci Monit       Date:  2012-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.